<DOC>
	<DOCNO>NCT01702285</DOCNO>
	<brief_summary>The main purpose study determine safety tolerability orally administer CUDC-101 cancer patient , determine dose test . This study also determine well CUDC-101 absorb blood give orally , assess CUDC-101 blood level happen study drug body , study body reacts study drug effect tumor . CUDC-101 administered cancer patient intravenous ( IV ) infusion research study , study give orally .</brief_summary>
	<brief_title>Phase I Study Assess Safety , Tolerability , Pharmacokinetics Orally Administered CUDC-101 Cancer Patients</brief_title>
	<detailed_description />
	<criteria>1 . Subjects histopathologically confirm diagnosis advance solid tumor . 2 . Subjects must standard care option . 3 . Measurable nonmeasurable disease 4 . Age ≥ 18 year 5 . ECOG performance status ≤ 2 6 . Life expectancy ≥ 3 month 7 . Women child bear potential must negative serum pregnancy test . 8 . Absolute neutrophil count ≥ 1,500/µL ; platelet ≥ 100,000/µL ; creatinine ≤ 1.5x upper limit normal ( ULN ) ; total bilirubin ≤ 1.5x ULN ; AST/ALT ≤ 2.5x ULN . For subject document liver metastasis , AST/ALT may ≤ 5x ULN 9 . Serum magnesium potassium within normal limit ( may supplement achieve normal value ) . 10 . Subjects brain metastasis eligible control stable dose ≤ 10mg prednisone/day equivalent dose steroid . 11 . Men woman child bear potential must agree use adequate birth control throughout participation study 60 day follow last study treatment . 12 . Able provide write informed consent follow protocol requirement . 1 . Systemic anticancer therapy within 28 day prior study treatment . Subjects prostate cancer LHRH hormonal therapy may enrol continue therapy . 2 . Use investigational agent ( ) within 21 day prior study treatment . 3 . Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigenpositive , know suspect active hepatitis C infection . 4 . Subjects receive moderate strong CYP3A4 CYP2D6 inhibitor within 7 day prior study treatment ( See Appendix C example ) . 5 . Serious infection require systemic antibiotic therapy within 14 day prior study treatment . 6 . Known gastrointestinal condition would interfere swallow oral absorption tolerance CUDC101 . 7 . Ongoing diarrhea grade ( per NCI CTCAE v4.03 ) . 8 . Uncontrolled severe cardiovascular disease , include myocardial infarct unstable angina within 6 month prior study treatment , New York Heart Association ( NYHA ) Class II great congestive heart failure , serious arrhythmia require medication treatment , clinically significant pericardial disease , cardiac amyloidosis . 9 . Unstable clinically significant concurrent medical condition would , opinion Investigator , jeopardize safety subject and/or compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>EGFR</keyword>
	<keyword>HDAC</keyword>
	<keyword>Her2</keyword>
	<keyword>Open-Label</keyword>
	<keyword>Dose-Escalation</keyword>
</DOC>